Together with AFP, the three miRNAs (miR-21, miR-122, miR-192) may serve as effective biomarkers to improve diagnostic therapy for HCC in HBV-positive patients, in particular, HBV-related liver cirrhosis with normal AFP levels or HCC with small tumor sizes [112]. The gene discussed is AFP; the disease is hepatocellular carcinoma.